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An analysis of the United States renal transplant patient population and
organ survival characteristics: 1977 to 1980. This study examines the
relationship between renal transplant organ survival and the extent of
HLA (human leukocyte antigen) A and B loci antigen matching.
Combined dialysis and transplant records for patients in the End Stage
Renal Disease Medical Information System (ESRD MIS), 1977 to 1980,
were analyzed to examine transplant organ survival characteristics and
changes in demographic pattern and donor types compared to previous-
ly reported studies of the United States transplant patients. Actuarial
survival curves for high match (3 or 4 HLA A and B loci antigen
matches) versus low match (0, 1, or 2 HLA A and B loci antigen
matches) groups were analyzed for their relative difference and its
statistical significance. In addition, this relationship was analyzed with
controls for age, sex, race, mixed lymphocyte culture (MLC), cross-
match, and prior time on dialysis. For both cadaver and living related
donor transplants, statistically significant differences were found be-
tween the survival curves of high and low match groups. Comparing
low match and high match groups, there were differences in 1-year
organ survival of 4.8 and 11.3%, respectively, for cadaver and living
related donor transplants. MLC negative and crossmatch positive
status appear to improve transplant organ survival beyond the effects of
HLA matching. The study also designates several methodological
problems inherent in transplant organ survival studies including: wheth-
er or not to include patient deaths as therapeutic failures, and whether
or not to analyze transplant organ survival at one point in time or to
compare overall survival curves for the entire study period.
Analyse des caracteristiques de Ia population de malades transplantes
renaux et de Ia survie d'organes aux etats-unis: 1977 a 1980. Cette etude
examine Ia relation entre Ia survie de reins de transpiantés et l'impor-
tance de la compatibilité HLA (antigène leucocytaire humain), pour les
locus A et B. Les dossiers combines de dialyse et de transplantation des
malades du End Stage Renal Disease Medical Information System
(ESRD MIS), de 1977 a 1980, Ont etc analyses pour examiner les
caractéristiques de Ia survie des organes transplantés, et les modifica-
tions de l'aspect demographique et des types de donrieurs par rapport
aux etudes prealablement rapportees de malades transplantés aux
Etats-Unis. Les courbes de survie actuarielles pour une forte compati-
bilité (compatibilite pour 3 ou 4 HLA A et B) par rapport a une faible
compatibilité (0, 1 ou 2 HLA A et B) ant ete analysées pour leur
difference relative et leur signification statistique. En plus, cette rela-
tion a etc analysee en contrôlant l'hge, le sexe, Ia race, les cultures
mixtes de lymphocytes (MLC), les crossmatch, et Ia periode de dialyse.
Pour les transplants a partir de cadavres ou de donneurs vivants
apparentes, des differences statistiquement significatives ont etc trou-
vees entre les courbes de survie pour les groupes a forte ou a faible
compatibilitë HLA. Ce travail met en evidence certains probldmes
methodologiques inherents aux etudes de survie des organes trans-
plantes: faut-il ou non considérer les deces comme des échecs therapeu-
tiques et faut-il ou non analyser la survie de l'organe transplante a un
moment dans le temps ou comparer les courbes globales de survie pour
Ia totalité de Ia periode considCrCe.
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The importance of HLA matching to cadaver transplant
organ survival is considered unresolved by many researchers
[1, 21. This issue was addressed in 1975 by the American
College of Surgeons (ACS 12th Report) utilizing a population
consisting of United States, European, and Canadian transplant
patients [3]. An improvement in transplant organ survival was
found in the ACS 12th Report with better HLA matching (Table
1). Two other major retrospective studies based on predomi-
nantly United States transplant patients did not find a statisti-
cally significant difference among different levels of HLA
matches in the transplant organ survival (Table 1) [4, 5].
None of these and other previous studies had the opportunity
to analyze combined dialysis and transplant records on the
same patients studied.
In 1977, the Health Care Financing Administration (HCFA)
took responsibility for the acquisition and dissemination of
information of United States transplant patients from the Amer-
ican College of Surgeons, National Transplant Registry. These
data are in the End Stage Renal Disease Medical Information
System data set which combines dialysis and transplant infor-
mation on ESRD patients. In this study, the HCFA ESRD data
set was used to describe the United States transplant population
between 1977 and 1980. Through these data, the relationship of
histocompatibility matching at the HLA A and B loci to
transplant organ survival in living related and cadaver donor
transplants was analyzed. Unfortunately, much information on
renal transplants performed during the period of study (1977 to
1980) was not reported to the HCFA. Because patient death
information was only partially reported to the ESRD MIS, this
study limited its focus to organ survival. The patient survival
aspect of the research cannot be addressed adequately in this
study due to insufficient data.
The relationship between HLA matching and transplant
organ survival was examined for the overall cadaver and living
related transplant groups and for subgroups of patients with
controls for age, sex, race, blood type, crossmatch, mixed
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Table 1. A comparison of HLA matching and cadaver donor first transplant organ survival in selected multicenter retrospective studies
Study
ACS 12th Report [11
288 transplant centers,
including 164 United
States centers; number
of states represented
unknown.
KTHS [3]
43 United States
transplant centers;
number of states
represented unknown.
Opelz et al [51
145 United States and
Canadian transplant
centers; number of
states represented
unknown.
Current study
135 United States
transplant centers; 39
states represented.
Data period
Sample patient size
Actuarial organ survival
percent difference
between "low" vs.
"high" HLA A and B
loci match at 1 year
1951 to 1972
1301
10%
1974 to 1976
1533
No statistically significant
difference reported.
1970 to 1975
4851
2%
1977 to 1980
3671
5%
Controlling factors which
improved the HLA
matching and organ
survival relationship
Not analyzed Male sex
Non 0 blood type
MLC negative
Crossmatch positive
a Estimate made from separate actuarial survival curves for 0, I. 2, 3, and 4 matches.
lymphocyte culture (MLC), and prior time on dialysis. The
demographic characteristics of the transplant population in the
study were compared to previously reported transplant studies
primarily based on United States transplant patients.
Two major methodological issues in evaluating transplant
organ survival were addressed in this study. The first concerns
the definition of organ survival, that is, whether patient deaths
prior to redialysis should be included in the computation of
actuarial life table percent organ survival. The second, whether
organ survival results should be reported at one point in time or
for the overall survival curves for the duration of the study
period.
Methods
Patient selection. Unit records (defined as information on a
particular patient relating to his dialysis and transplant therapy
stored under one system-unique identifier) were obtained from
the End Stage Renal Disease Medical Information System,
HCFA, of the United States Department of Health and Human
Services. The data set included approximately 102,000 ESRD
patients treated by dialysis or transplantation (or both) during
the period from January 1, 1977, through June 30, 1980. Of an
estimated 12,000 renal transplants1 that were performed during
this period, 6366 with first transplants had HCFA tissue typing
information forms available. From these, 3671 patients were
included in our analysis. The remaining patients were excluded
due to lack of: (1) two or more HLA antigens identified, (2)
donor type, and (3) transplantation date.
Patients were divided into groups according to: (1) age, less
than 15 years, 15 to 54 years, or greater than 55 years; (2) race,
white or nonwhite (nonwhites included blacks, American mdi-
'This figure was estimated from a tabulation of inpatient billing forms
with a surgical procedure code for transplantation. Completeness and
reliability of this record were not verified.
ans, and orientals); (3) blood type, 0 and non-O (non-O included
types A, B, and AB); (4) MLC, positive and negative; (5) donor
specific crossmatch, positive or negative; and (6) prior time on
dialysis, 3 months or less or greater than 3 months of dialysis
prior to transplantation. All information concerning HLA
matching, donor specific crossmatch, and MLC reports were
obtained from HCFA tissue typing forms. Information concern-
ing the methods used to perform tissue typing, MLC testing and
crossmatch used by the reporting centers was not available in
the ESRD MIS. The definition of positive and negative MLC
according to degree of MLC reactivity was also not available in
the ESRD MIS. Crossmatch and mixed lymphocyte culture
results were reported as positive, negative, not performed, or
equivocal. Equivocal test results were excluded from our
analysis. High match patients were defined as those patients
with three or four matches at the HLA A and B loci. Low match
patients were those with 0, 1, or 2 HLA A and B loci matches.
Computations. Transplant organ survival was calculated us-
ing the standard actuarial life table method [61. Patient data
were available by quarters (3-month periods). Graft organ
survival time was defined as the interval between the date of
transplantation and the beginning of dialysis therapy of two
consecutive quarters, or longer, subsequent to date of trans-
plantation. Actuarial survival curves were computed for living
related and cadaver donor transplants for the overall high
versus low match groups and for the subgroups as listed above.
Low and high match organ survival curves for the 3-year period
of analysis (1977 to 1980) were compared for their relative
statistical difference utilizing the Wilcoxen-Breslow (WB) test
statistics. This method compares the entire survival curves for
high and low match groups and analyzes the probability that the
two curves did not differ by chance.
Results
Description of study population. The ESRD MIS data set
consisted of the pertinent patient information from 135 centers
Data utilized
Not analyzed
Renal transplant patient population and organ survival 687
Table 2. Changes in transpiant recipient racea
Year
Recipient race
% White % Nonwhite
1971
1972
1973
1974
1977 to 1980
87.1
86.6
84.2
82.9
78.6
12.9
13.4
15.8
17.1
21.4
Race data for 1971 to 1974 are based on the 13th Report of the
Human Renal Transplant Registry by the American College of Surgeons
[8], while 1977 to 1980 data are based on the current study.
Table 3. Changes in transplant donor type
Year % Cadaver
Donor typea
% Living
relative
1971 68.2 31.8
1972 67.3 32.5
1973 70.4 29.6
1974 NAb NA
1977 to 1980 77.7 22.3
a Donor type data for 1971 to 1974 are based on the 12th Report of the
Human Renal Transplant Registry by the American College of Surgeons
[3], while 1977 to 1980 data are based on the current study.
b Not available.
in 39 states. The race distribution of renal transplant recipients
was 78.6% white and 21.4% nonwhite. The percentage distribu-
tion of nonwhite renal transplant recipients has increased
progressively from 12.9% in 1971 to 21.4% in the present study
(Table 2) [8]. The sex ratio of the renal transplant recipients in
this study was 65% male, 35% female, which has not changed
appreciably from the ratio reported in the 13th Report by the
American College of Surgeons (62% male and 38% female) [81.
Ninety-six percent of the patients in this study were between
the ages of 15 and 54, with approximately 2% each in the age
groups less than 15 and greater than 55, and 0.4% were greater
than 65 years of age. There was a progressive increase in the
percentage of cadaver donor transplants from 68.2% in 1971 to
77.7% in the present study (Table 3) [31. Among patients with
HCFA ESRD MIS tissue typing forms submitted, 20% had one
or more of the 11 data items missing (Table 4).
Causes of death. Among the 116 patients with causes of death
reported, 44 (38%) were related to infection, and 41(35%) were
cardiovascular or cerebrovascular in origin (Table 5). These
results, as well as the distribution of the causes of death, are
similar to other reported studies [9, 10].
Effect of high versus low HLA A and B loci match on
transplant organ survival
Cadaver donor transplants (Fig. 1 and Table 6). For cadaver
donor transplants, the overall 3-year survival curves for high
and low matches were statistically different from each other
(WB 3.8, P < 0,05). A statistically significant difference
between high and low match curves was also indicated for MLC
negative transplants. (It should be noted that MLC results are
Table 4. Percent not reported: By items of HCFA ESRD MIS
transplant data seta
Data items
% Not
reported
Donor type 12.6
24Donor age
20.7Donor sex
Donor race 22.5
Donor blood type 20.8
18.8Recipient race
19.7Recipient blood type
19.2Crossmatch
MLC
a From the 6,366 patients with HCFA tissue typing forms available.
Table 5. Causes of death
Data items N %
Cardiac 26 22.4
Cerebrovascular 15
Pulmonary embolism 7
11.2Hemorrhage (including GI)
44 38.0Infection
Hyperkalemia 6
1 0.9Pancreatitis
Malignancy 2
1 0.9Withdrawal from dialysis
0.9Suicide 1
Total 116 100
not usually reported for cadaver transplants, but 140 MLC
reports were contained in the ESRD MIS.) White, female, and
blood type 0 recipients also indicated a trend toward improve-
ment in organ survival with better HLA matching (WB = 2.6, P
 0.06 for all three). Age and prior time on dialysis did not have
a statistically significant effect on organ survival.
Living related donor transplants (Fig. 2 and Table 7). In
living related donor transplants, the overall high and low match
curves were statistically different from each other (WB = 18.00,
P < 0.00001). The curves were also significantly different in
MLC negative, crossmatch negative transplants, and in recipi-
ents of both blood types 0 and non-0, white and male recipients
(WB = 4.0, P < 0.05). Females and nonwhites did not indicate a
significant difference in high versus low match survival curves.
Actuarial percent survival difference at 1 year (Tables 6 and
7). The 1-year overall graft survivals for high and low match
cadaver donor transplants were 68.4 and 63.5%, respectively, a
difference of 4.8%. The percentages for living related trans-
plants were 82 and 71%, respectively, a difference of 11%.
For both cadaver and live related donor transplants with
reported negative MLC reaction, a higher percentage organ
survival at 1 year was indicated for the high match group
relative to the low match group with a difference of 29.9% in
cadaver transplants and 13.8% in live related transplants. A
similar result was seen for crossmatch positive cadaver trans-
plants with a 56.3% difference in organ survival between high
and low match groups, although the sample size was only 16.
There were no living related transplants with positive cross-
match in the study population.
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Fig. I. Actuarial percent survival for cadaver donor organ group.
Patients who died before redialysis were excluded. N equals 2743
(surviving organs = 1770; organ failure = 973). The solid line represents
the low match group (0, 1, 2 matches). The broken line represents the
high match group (3, 4 matches).
For both cadaver and live related donor transplants with
positive MLC reactions a lower percent organ survival was
indicated for the high match group relative to the low match
group with a difference in percent survival at 1 year of 44.8% in
cadaver transplants and 6.8% in live related transplants.
Discussion
The data utilized in this study has several limitations. First,
out of the estimated 12,000 transplants performed during the
study period, only 30% (approximately) of the patients were
included in this study, due to incomplete reporting.
The study population may not be a random sample of the total
transplant population for this period. Thus, the inferences made
in this study may not be valid for the total United States
transplant population, Another limitation of the ESRD MIS
data is that only a small proportion of patient death is reported.
Therefore, analysis of patient survival could not be performed.
Completeness of reporting has been a major problem with the
ESRD MIS and the motivation for completing the HCFA forms
has been financial. Reporting of deaths is not necessary for
reimbursement for ESRD services and is the presumed reason
for the low rate of patient death reporting. On the other hand,
reporting of the return of a transplant patient to dialysis was
substantially more accurate since receipt of this information by
HCFA was required for reimbursement. Thirdly, those patients
whose record was complete enough to be included in this study
may have had incorrectly reported information. For example, a
positive donor-specific crossmatch is usually an absolute con-
traindication to the performance of a renal transplant. Never-
theless, 16 such patients were contained in the data set.
Similarly, while most institutions would not perform a MLC
positive live related donor transplant, 102 such patients existed
in the data we analyzed.
For those patients whose HLA tissue typing, MLC reactions,
and crossmatch status were recorded on the HCFA tissue
typing form, information concerning the methods used to
perform these tests was not available. Thus, the degrees of
uniformity in test procedures could not be verified. Therefore,
the resulting information reported to the ESRD MIS is suspect
in its reliability.
Despite these limitations, this analysis, to our knowledge, is
the first summary of the United States national transplant
experience since the termination of the American College of
Surgeons' Renal Transplant Registry in 1976. In addition,
although the study population might not be the random sample
of the total United States transplant patient population for the
study period, it is composed of patients from 39 states and 134
centers. Thus, it may well be considered representative in many
respects. Also, the ESRD MIS contains combined dialysis and
transplant records. Thus, return of a transplant patient to
dialysis could be determined reliably.
The 12th and 13th Reports based on by the Transplant
Registry of the American College of Surgeons, included Euro-
pean and Canadian transplantations in addition to the United
States transplantation data. Our study was based exclusively
upon United States transplantations and may not be fully
comparable. Nevertheless, one can see a trend of increase in
the percentage of nonwhite renal transplant recipients and
cadaver donor transplants from 1971 to the present study. The
9.1% increase in the proportion of nonwhite recipients may
correspond to the 9.5% increase in the proportion of cadaver
donor recipients (Tables 2 and 3), and may reflect the fact that
87% of the transplants performed in nonwhites were from
cadaver donors. Only 4% of the transplant patients were less
than 15 years of age or older than 55. The number of transplants
with adequate completeness of reported data in this study was
approximately 30% of the total estimated transplants performed
during the period of the study (1977 through 1980). This
compares favorably to the 12th Report by the American College
of Surgeons, in which approximately 24% of the first trans-
plants reported to the Registry had tissue typing information
available for analysis.
The results of this study indicate that HLA matching im-
proves transplant organ survival in live related donors as well as
cadaver donor transplants. The latter result has not been
reported in many transplant studies. Nevertheless, three out of
four large multicenter retrospective studies, based largely on
United States transplant population data, indicate improvement
in cadaver transplant organ survival with better HLA matching
(Table 1). Extrapolations from those studies show results
similar to ours for cadaver donor organ transplants, with a
range of 2 to 10% larger 1-year graft survival of high match
groups comparing to low match groups. In this study, larger I-
year graft survival percents of 4.8 in cadaver transplants and
11.3% in living related transplants were indicated for high
match groups comparing to low match groups.
Although it is convenient to talk about graft survival at 1 year
or at any given point in time, we chose to analyze organ survival
by comparing the difference between the entire 3-year survival
curves for high versus low match groups. The rationale for this
is the differences between the high and low match group curves
at each time interval are uneven. For example, the largest
differences between the survival curves occurred during the
100
80
W8 = 38, P = 0.05
40
20
'4 '4 1 2
Post-transp'ant, years
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Table 6. Acturial percent survival—cadaver donor organs
Controlling factors
Survival time for low and high matches
Nb
.Wilcoxon/Breslow
test statistica P valueab3 Months 6 Months 1 Year 2 Years 3 Years
Overall
% Survival for low match 74.9 68.0 63.6 60.0 57.1 2743 3.82 0.03
% Survival for high match 77.2 72.3 68.4 65.6 65.6
Crossmatch (—)
% Survival for low match 75.2 69.0 64.0 60.4 57.4 2670 3.10 0.04
% Survival for high match 78.9 72.6 68.5 65.6 65.6
Crossmatch (+)
% Survival for low match 80.0 60.0 25.5 12.7 — 16 2.90 0.05
% Survival for high match 100.0 81.8 81.8 81.8
MLC (—)
% Survival for low match 74.1 68.2 61.0 56.1 56.1 81 2.90 0.05
% Survival for high match 90.9 90.9 90.9 90.9
MLC (+)
% Survival for low match 80.0 72.0 69.4 69.4 69.4 59 1.90 —
% Survival for high match 50.0 50.0 25.0 — —
Recipient blood type (type
0)
% Survival for low match 75.6 68.9 64.7 59.5 56.8 1207 2.60 0.06
% Survival for high match 82.5 74.3 70.9 68.5 68.5
Recipient blood type (non 0)
% Survival for low match 74.6 67.3 63.0 60.7 57.4 1507 1.05 0.15
% Survival for high match 76.4 72.4 66.1 62.9 58.6
Recipient race (white)
% Survival for low match 76.2 71.3 67.3 58.3 53.7 612 2.57 0.06
% Survival for high match 84.3 77.3 72.9 72.9 72.9
Recipient race (nonwhite)
% Survival for low match 74.9 66.4 63.8 55.3 48.6 224 0.42 0.26
% Survival for high match 63.0 63.0 57.2 57.2 57.2
Abbreviation: MLC, mixed lymphocyte culture.
Wilcoxon-Breslow (WB) test statistics analyze the statistical significance concerning the relative differences between the curves; a one-tail P
value is reported for the statistical significance of the given WB. A WB test value greater than 3.8 and P value for each of less than 0.05 is
considered statistically significant. Subgroup numbers are smaller than overall group numbers since they include data for the controlling factors as
well as for a HLA match.
b Both N and P values apply to high and low matches.
first 6 to 12 months (Tables 6 and 7), with much less difference
after 1 year. Therefore, analysis of survival at one point in time
may result in either an overestimation or underestimation of the
overall differences in organ survival between high and low
match groups. For example, in Table 6, the percentage survival
difference at 3 months for the overall cadaver group was 2.3%, a
relatively small difference, while the entire survival curves are
substantially different. In this study, percent survival at various
points in time is reported for comparison purposes with other
studies. Moreover, selection of a single time point is arbitrary
and allows for investigator bias to effect comparisons.
The 1-year graft survival for cadaver donor transplants was
approximately 10% higher in our study than those in Table 1.
These higher values are due to our definition of graft failure,
which excluded deaths prior to redialysis. Two studies that
excluded deaths (with a functioning kidney), for the calculation
of graft survival respectively found 10 and 19% higher 1-year
organ survival when deaths were excluded than when they
included deaths prior to patient's return to dialysis [11, 12].
The exclusion of deaths prior to a transplant patient's return
to dialysis in the computation of organ survival may be valid for
several reasons. Our analysis of the reported causes of death
revealed that 38% were related to infection. If we presuppose
that all infectious deaths were related to immunosuppression to
overcome HLA incompatibility, and the remaining 62% were
not related immunologically (non-HLA related deaths), then the
inclusion of these deaths would have resulted in a bias toward a
lower percent survival. If the primary focus of a transplant
study is the relationship of HLA matching to graft survival,
exclusion of these deaths may be valid. Admittedly, inclusion of
patient deaths in actuarial survival computations are of great
practical importance to advise a patient as to his possible fate
after transplantation.
For cadaver donor transplants with a positive crossmatch,
improved survival with better HLA matching was indicated.
These crossmatch positive "presensitized" patients may have
selected out more compatible transplants with better matching
outside the HLA A and B loci, that is, "D" (MLC negative) or
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Fig. 2. Actuarial percent survival for living related donor organ group.
Patients who died before redialysis were excluded. N = 928 (surviving
organs = 701; organ failure 227). The solid line represents the low
match group (0, 1, 2 matches). The broken line represents the high
match group (3, 4 matches).
DR loci. Several studies have noted this enhanced effect of
HLA matching in presensitized patients [131.
The importance of the "D" locus can be seen in cadaver and
live related donor transplants since they both showed nearly a
30% difference in graft survival at 1 year between high and low
match groups. As mentioned, the reliability of MLC data may
be considered suspect. Nevertheless, as in this study, improve-
ment in cadaver donor graft survival with low mixed lympho-
cyte culture reaction was found in one previously reported
study by Cockrum et al [14], In their study, out of 59 cadaveric
graft recipients, 37 had low MLC's. Thus, the ratio of low MLC
to high MLC in their study was 1.6 to 1 for these cadaver donor
recipients. In this study, a similar ratio, 1.3 to 1 of negative to
positive MLC reactions was found. Whether the negative MLC
in this study corresponds quantitatively to the low MLC of the
previously reported study by Cockrum et al [141 cannot be
determined. The results from both studies need to be verified by
further evaluation of MLC reactions in cadaver donor recipient
pairs. The improvement in graft survival, with negative (low)
MLC reactions may be due to DR locus antigen matching in
these MLC negative transplants, since the D and DR loci may
be linked genetically 1151; or, DR antigens may be identical to
the HLA D specificities [1J. For both cadaver and live related
transplants with positive MLC reactions, the smaller percent
survival in the high match groups relative to low match groups
may indicate that D locus matching supercedes the effects of
HLA A and B loci matching on graft organ survival. Unfortu-
nately, the value of the MLC reaction in cadaver donor
selection is negated by the fact that the results of the test
usually cannot be obtained prior to the transplant.
The lack of statistically significant differences in organ sur-
vival in subgroups of cadaver and live related donors (Tables 6
and 7) may be due to their smaller sample size than the overall
groups, or because of an actual disadvantage caused by the
controlling factor with respect to organ survival. The trends
toward improved survival with better HLA matching in cadaver
with blood type 0 and female recipients of cadaver organs are
opposite of previously reported results [5]. Blood type 0
recipients receive transplants from only other blood type 0
donors and this may cause an advantage relative to the non-O
blood group recipients. Female recipients may be presensi-
tized" after pregnancy and "select out" better matched
kidneys.
The information on the transfusion status, receipt of antilym-
phocyte serum, pretransplant splenectomy, and the general
medical condition of the patients in the low versus high match
groups were not available in the ESRD MIS.
In conclusion, despite the substantial limitations of the ESRD
MIS data on which this study was based, this study analyzes
and presents, to our knowledge, the first United States national
renal transplant experience since the 13th Report of the Human
Renal Transplant Registry by ACS in 1977. Because of the data
problems, definitive statements concerning transplant organ
survival cannot be made. Nevertheless, the statistically signifi-
cant differences in organ survival between high (3 or 4 HLA A
and B loci matches) versus low (0, 1, or 2 HLA A and B loci
matches) match for live related and cadaver donor groups
appear to be valid. Thus, the results of this study do not point to
a need to change in the current practice of utilizing HLA
matching in renal transplantation. On the other hand, one can
argue that for cadaver donor transplants the 5% (P < 0.03)
difference in 1-year survival comparing high versus low match
groups may not justify delaying transplantation of a cadaver
donor organ until a "high" match recipient can be found.
The difference in survival indicated in this study between
high and low HLA A and B loci match groups was more
pronounced in those cadaver and living related donor transplant
recipients who were MLC negative and in those cadaver donor
transplant recipients with cross-match positive reactions. This
difference may be related to matching in the DR locus and
possibly other histocompatibility factors.
Comparing the results based on the ESRD MIS data to the
results of previously reported primarily United States trans-
plant studies, the proportions of nonwhite renal transplant
recipients and cadaver donor recipients have both increased
between 1971 to 1980 by almost 10%. This may be explained by
the predominance of cadaver donor transplants in nonwhite
recipients.
Comparing the methodology of this study to several other
major retrospective studies: This study (1) is based exclusively
on the United States national transplant population, (2) is based
on the interpretation of whole survival curves for the study
period as well as one point in time, and (3) excludes death prior
to redialysis in assessing organ failure. These issues should be
considered in future studies.
To adequately address the preliminary findings of this study
and those reported by the previous studies of United States
renal transplants, a substantial modification of the ESRD MIS
is necessary. This modification effort should include the expan-
sion of the range of information items to be collected and devise
methods to improve the compliance of data reporting, reliabil-
ity, and uniformity.
100
80
WB= 18,P0.00001
40
20
2
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Table 7. Acturial percent survival—living related donor organs
Controlling factors
Survival time for low and high matches
Nb
.Wilcoxon/Breslow
test statistica P value3 Months 6 Months 1 Year 2 Years 3 Years
Overall
% Survival for low match
% Survival for high match
82.2
88.6
73.9
85.7
70.7
82.0
64.4
79.4
64.4
76.2
928 18.00 0.001
Crossmatch (—)
%Survivalforlowmatch
% Survival for high match
82.3
88.7
73.9
85.7
70.2
82.2
64.3
79.5
64.3
76.2
916 18.19 0.001
Crossmatch (+)
% Survival for low match
% Survival for high match
—
—
•—
•—
—
—
—
—
—
—
—
—
MLC (-)
% Survival for low match
% Survival for high match
82.9
88.5
73.3
86.7
70.4
84.2
63.7
80.3
63.7
76.4
376 8.37 0.005
MLC (+)
% Survival for low match
% Survival for high match
81.0
82.2
77.1
67.3
74.1
67.3
68.7
67.3
65.7
—
102 0.38 —
Recipient blood type (type 0)
% Survival for low match
% Survival for high match
81.4
86.8
74.2
84.1
71.1
80.1
64.9
80.1
64.9
80.1
402 5.77 0.01
Recipient blood type (non 0)
% Survival for low match
% Survival for high match
82.3
89.8
73.2
86.8
67.8
83.2
64.3
78.8
64.9
73.3
480 11.59 0.001
Recipient race (white)
% Survival for low match
% Survival for high match
80.5
85.3
68.0
81.8
68.0
77.6
58.2
66.8
58.2
61.0
240 3.02 0.04
Recipient race (nonwhite)
% Survival for low match
% Survival for high match
87.5
94.1
87.5
87.6
87.5
77.9
87.5
77.9
87.5
—
33 0.03 0.43
Abbreviation: MLC, mixed lymphocyte culture.
a Wilcoxon-Breslow (WB) test statistics analyze the statistical significance concerning the relative differences between curves; a one-tail P value
is reported for the statistical significance of the given WB. A WB test value greater than 3.8 and P value for each of less than 0.05 is considered sta-
tistically significant. Subgroup numbers are smaller than group numbers since they include data for the controlling factors as well as for a HLA
match.
Both N and P values apply to high and low matches.
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